Association of antiphospholipid assays with stroke.
| Assay | Stroke, n = 53 No. (% positive) | No Stroke, n = 273 No. (% positive) | OR 95% CI* | p (adjusted)* | |
|---|---|---|---|---|---|
| IgG | Anti-ß2-GPI | 5 (9) | 19 (7) | 2.0 (0.7, 6.2) | 0.21 |
| Anti-ß2-GPI D1 | 3 (6) | 17 (6) | 1.1 (0.3, 4.1) | 0.89 | |
| aCL | 7 (13) | 31 (11) | 1.6 (0.6, 4.1) | 0.33 | |
| Anti-PS/PT | 8 (15) | 32 (12) | 2.5 (1.0, 6.3) | 0.062 | |
| IgM | Anti-ß2-GPI | 2 (4) | 15 (5) | 0.7 (0.2, 3.3) | 0.66 |
| aCL | 8 (15) | 25 (9) | 1.6 (0.7, 4.1) | 0.28 | |
| Anti-PS/PT | 14 (26) | 54 (20) | 1.6 (0.8, 3.2) | 0.21 | |
| IgA | Anti-ß2-GPI | 17 (32) | 55 (20) | 1.9 (1.0, 3.7) | 0.070 |
| aCL | 4 (8) | 8 (3) | 2.0 (0.6, 7.4) | 0.28 | |
| Anti-ß2-GPI D4/5 | 16 (30) | 47 (17) | 2.2 (1.1, 4.4) | 0.033 | |
| IgG/M | Anti-PS/PT | 11 (21) | 51 (19) | 1.5 (0.7, 3.2) | 0.35 |
| LAC** | dRVVT | 17 (39) | 54 (23) | 2.3 (1.1, 4.8) | 0.022 |
↵* Adjusted for age, sex, and ethnicity.
↵** Forty-three patients did not have dilute Russell viper venom test (dRVVT) results available. Thus, the total number of patients for the thrombosis group was 44, and the no-thrombosis group, 239. Anti-ß2-GPI: anti-ß2-glycoprotein I; anti-ß2-GPI D1: anti-ß2-glycoprotein I domain 1; aCL: anticardiolipin; anti-PS/PT: antiphosphatidylserine/prothrombin; LAC: lupus anticoagulant; anti-ß2-GPI D4/5: anti-ß2-glycoprotein I domain 4/5.